Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to compare, after 8 weeks, the efficacy of SR58611A vs.
placebo in patients with Major Depressive Disorder who are on concomitant treatment with
escitalopram.
The secondary objective of this study is to document clinical safety and tolerability of
SR58611A in association with escitalopram.